



Assoc. Prof. Monika Bartekova, MD, PhD
(Bratislava, Slovakia)

Dr. Bartekova is Assoc. Professor of Normal and Pathological Physiology and Head of the Department of Cardiovascular Physiology and Pathophysiology at the Institute for Heart Research, Centre of Experimental Medicine, Slovak Academy of Sciences.

After receiving her MSc. degree in Biochemistry from the Comenius University in Bratislava in 1996, she completed her PhD. degree at Institute for Heart Research, Slovak Academy of Sciences in 2005. Since 2014 she became Senior Research Associate and the principal investigator of 4 research projects at the Institute for Heart Research SAS. During her career she absolved 2 study stays at foreign research institutions, Max Planck Institute in Bad Nauheim, Germany in 1997, and Manitoba Research Centre in Winnipeg, Canada in 2015. Since 2011 she established as a teaching associate at the Medical Faculty of Comenius University in Bratislava where she habilitated in Normal and Pathological Physiology in 2018.

Currently, she holds the position of the Head of the Department of Cardiovascular Physiology and Pathophysiology at the Institute for Heart Research, Centre of Experimental Medicine SAS; she supervises three PhD. students, she is the vice-chair of the Scientific Board of the Centre of Experimental Medicine, Scientific Secretary of the Institute for Heart Research, and the principal investigator of three national research projects. She was/is a Management Committee (MC) member of two COST projects related to cardioprotection (EU-CARDIOPROTECT and CardioRNA) and a member of one Cost Implementation Grant (IMPACT). She is a council member of the European Section of International Academy of Cardiovascular Sciences (IACS) and a member of Editorial Board of the journal Molecular and Cellular Biochemistry.

The main area of her research is ischemia-reperfusion (I/R) injury of the heart and cardioprotection, with a special focus on the effects of natural substances, mainly flavonoids, and pharmacological treatments in myocardial I/R, role of ageing and metabolic comorbidities in cardioprotection, as well as revealing the molecular mechanisms involved in cardiac I/R injury and cardioprotection by various interventions.